99mtc-rhannexin

Small moleculeexperimentalImaging agent

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2013 (NCT02182609)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
99-technetium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 99mtc-rhannexin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02182609Phase 1Apr 1, 2013Advanced Accelerator Applications, Atreus Pharmaceuticals Corporation, University of Ottawa
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Advanced Accelerator ApplicationsFor profit1112013
Atreus Pharmaceuticals CorporationFor profit1012013
University of OttawaAcademic/Hospital1012013
3 organizations
Page 1 / 1